Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)
Annexon (ANNX) has granted stock options to a new non-executive employee as part of its 2022 Employment Inducement Award Plan. The equity award, approved on March 12, 2025, complies with Nasdaq Listing Rule 5635(c)(4).
The grant includes options to purchase 35,000 shares of Annexon common stock with a ten-year term and an exercise price of $2.60 per share, matching the closing price on March 14, 2025. The options vest over 4 years, with 25% vesting after the first year and the remaining 1/48th vesting monthly thereafter, contingent on continued employment.
Annexon (ANNX) ha concesso opzioni su azioni a un nuovo dipendente non esecutivo nell'ambito del suo Piano di Indennità per l'Occupazione 2022. L'assegnazione di azioni, approvata il 12 marzo 2025, è conforme alla Regola di Quotazione Nasdaq 5635(c)(4).
Il grant include opzioni per acquistare 35.000 azioni ordinarie di Annexon con un termine di dieci anni e un prezzo di esercizio di $2,60 per azione, corrispondente al prezzo di chiusura del 14 marzo 2025. Le opzioni si maturano in 4 anni, con il 25% che matura dopo il primo anno e il restante 1/48 che matura mensilmente successivamente, a condizione di un impiego continuato.
Annexon (ANNX) ha otorgado opciones sobre acciones a un nuevo empleado no ejecutivo como parte de su Plan de Premios por Inducción de Empleo 2022. La concesión de acciones, aprobada el 12 de marzo de 2025, cumple con la Regla de Cotización de Nasdaq 5635(c)(4).
La concesión incluye opciones para comprar 35,000 acciones ordinarias de Annexon con un plazo de diez años y un precio de ejercicio de $2.60 por acción, que coincide con el precio de cierre del 14 de marzo de 2025. Las opciones se consolidan durante 4 años, con el 25% consolidándose después del primer año y el restante 1/48 consolidándose mensualmente a partir de entonces, sujeto a la continuidad del empleo.
Annexon (ANNX)은 2022년 고용 유인 보상 계획의 일환으로 새로운 비상임 직원을 위해 주식 옵션을 부여했습니다. 2025년 3월 12일에 승인된 이 주식 보상은 나스닥 상장 규정 5635(c)(4)를 준수합니다.
이번 부여는 35,000주의 Annexon 보통주를 구매할 수 있는 옵션을 포함하며, 10년의 기간과 주당 $2.60의 행사 가격을 가지고 있으며, 이는 2025년 3월 14일의 종가와 일치합니다. 이 옵션은 4년에 걸쳐 발생하며, 첫 해가 지나면 25%가 발생하고, 이후 매달 1/48씩 발생하며, 계속 고용된 경우에 한합니다.
Annexon (ANNX) a accordé des options d'achat d'actions à un nouvel employé non-exécutif dans le cadre de son Plan d'Attribution d'Induction à l'Emploi 2022. L'attribution d'actions, approuvée le 12 mars 2025, est conforme à la Règle de Cotation Nasdaq 5635(c)(4).
Cette attribution comprend des options pour acheter 35 000 actions ordinaires d'Annexon avec une durée de dix ans et un prix d'exercice de 2,60 $ par action, correspondant au prix de clôture du 14 mars 2025. Les options se libèrent sur 4 ans, avec 25 % se libérant après la première année et le reste se libérant mensuellement par la suite, sous réserve d'un emploi continu.
Annexon (ANNX) hat einem neuen nicht-executive Mitarbeiter im Rahmen seines Beschäftigungsanreizplans 2022 Aktienoptionen gewährt. Die Aktienauszeichnung, die am 12. März 2025 genehmigt wurde, entspricht der Nasdaq-Listing-Regel 5635(c)(4).
Die Gewährung umfasst Optionen zum Kauf von 35.000 Aktien der Annexon-Stammaktien mit einer Laufzeit von zehn Jahren und einem Ausübungspreis von $2,60 pro Aktie, der dem Schlusskurs vom 14. März 2025 entspricht. Die Optionen werden über 4 Jahre fällig, wobei 25% nach dem ersten Jahr fällig werden und die restlichen 1/48 monatlich danach, abhängig von einer fortgesetzten Beschäftigung.
- None.
- None.
BRISBANE, Calif., March 17, 2025 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with devastating classical complement-mediated neuroinflammatory diseases of the body, brain, and eye, today announced that it has granted inducement to a new non-executive employee under the terms of the 2022 Employment Inducement Award Plan. The equity award was approved on March 12, 2025, in accordance with Nasdaq Listing Rule 5635(c)(4).
The new non-executive employee received an option to purchase 35,000 shares of Annexon common stock. The option carries a ten-year term and an exercise price per share equal to
About Annexon
Annexon Biosciences (Nasdaq: ANNX) is developing therapeutics that stop classical complement-driven neurodegeneration as first-in-kind treatments for millions of people living with serious neuroinflammatory diseases of the body, brain and eye. Our novel scientific approach focuses on C1q, the initiating molecule of classical complement’s potent inflammatory pathway that when misdirected can lead to tissue damage and loss. By targeting C1q, our immunotherapies are designed to stop this neuroinflammatory cascade in disease before it starts. Our pipeline spans three diverse therapeutic areas – autoimmune, neurodegenerative and ophthalmic diseases – and includes targeted investigational drug candidates designed to address the unmet needs of over 8 million people worldwide. Annexon’s mission is to deliver game-changing therapies to patients so that they can live their best lives. To learn more visit annexonbio.com.
Investor Contact:
Joyce Allaire
LifeSci Advisors
jallaire@lifesciadvisors.com
FAQ
What stock options did Annexon (ANNX) grant to its new employee in March 2025?
How does the vesting schedule work for ANNX's March 2025 employee stock options?
What was Annexon's (ANNX) stock price on March 14, 2025?
Under which regulatory rule was ANNX's employee stock option grant approved?
